Clinical Trial Update: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) [Phase 2, Phase 3]

View source ↗

Summary

SWOG reports a Phase 2/3 trial evaluating N-803 (ALT-803) in combination with pembrolizumab versus standard treatment for advanced non-small cell lung cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING